×

in vivo PK & PD

Our organizational mission to advance science from research bench to hospital bed is facilitated by our capabilities in pharmacokinetics (PK) and pharmacodynamics (PD). In collaboration with various business units within both the Laboratory Testing Division and the WuXi AppTec corporation as a whole, in vivo PK & PD studies enable our clients to balance the efficacy of their products with potential toxicity early on, thereby mitigating the risk of clinical failure down the line. Our integrated approach brings together scientists from in vivo pharmacology in different disease areas, bioanalysis, pharmacokinetics and toxicology to ensure each study is performed on time, within regulatory guidelines and to the specifications of each individual project.

+ State-of-the-Art AAALAC-Accredited Facilities
+ OLAW Assurance for PHS Funding
+ Over 85 Well-Trained & Dedicated Staff
+ Over 500 Arms Dosed per Week
+ Rapid Turnaround Times

in vivo ADME/ PK & PD Capabilities
+ IV Infusion in Living Animals with Behavioral Testing
+ Behavioral Test, Biomarker, RO in the Same Animal
+ Microdialysis, Compound Exposure in the Same Animal
+ NCE-Related in vivo PK Studies for Exposure & Bioavailability
+ Dose Linearity PK and Pilot Toxicology Studies
+ Single and Cassette PK
+ Tissue Distribution
+ Dose Escalation
+ Multiple Doses
+ Formulation / Salt Form Evaluation
+ Mass Balance (3H and 14C)
+ Metabolite Radioprofiling & ID
+ Quantitative Tissue Dissection (QTD)
+ Quantitative Whole-Body Autoradiography (QWBA)
+ Small-Scale Isolation Purification & Definitive Structural ID of Metabolites by NMR

Biological Matrix Collection
+ Blood
+ Plasma
+ Serum
+ Bile
+ Urine
+ Feces
+ CSF
+ Bone Marrow
+ Tissue Samples
+ Tumors
+ Lymph Fluid